RT Journal Article
T1 Mid-regional pro-adrenomedullin, methemoglobin and car-boxyhemoglobin as prognosis biomarkers in critically ill pa-tients with COVID-19: an observational prospective study
A1 Oblitas, Christian Mario
A1 Galeano Valle, Francisco
A1 Ramírez Navarro, Jesús
A1 López Cano, Jorge
A1 Monterrubio Manrique, Ángel
A1 García Gámiz, Mercedes
A1 Sancho González, Milagros
A1 Arenal López, Sara
A1 Álvarez-Sala Walther, Luis Antonio
A1 Demelo Rodríguez, Pablo
AB Mid-regional pro-adrenomedullin (MR-proADM), methemoglobin (MetHb), and carboxyhemoglobin (COHb) levels have been associated with sepsis. In this study, we assessed the role of this potential biomarkers in critically ill COVID-19 patients. Outcomes were mortality and a combined event (mortality, venous or arterial thrombosis, and orotracheal intubation (OTI)) during a 30-day follow-up. A total of 95 consecutive patients were included, 51.6% required OTI, 12.6% patients died, 8.4% developed VTE, and 3.1% developed arterial thrombosis. MetHb and COHb levels were not associated with mortality nor combined event. Higher MR-proADM levels were found in patients with mortality (median of 1.21 [interquartile range-IQR-0.84;2.33] nmol/L vs. 0.76 [IQR 0.60;1.03] nmol/L, p = 0.011) and combined event (median of 0.91 [IQR 0.66;1.39] nmol/L vs. 0.70 [IQR 0.51;0.82] nmol/L, p < 0.001); the positive likelihood ratio (LR+) and negative likelihood ratio (LR−) for mortality were 2.40 and 0.46, respectively. The LR+ and LR− for combined event were 3.16 and 0.63, respectively. MR-proADM ≥1 nmol/L was the optimal cut-off for mortality and combined event prediction. The predictive capacity of MR-proADM showed an area under the ROC curve of 0.73 (95% CI, 0.62–0.81) and 0.72 (95% CI, 0.62–0.81) for mortality and combined event, respectively. In conclusion, elevated on-admission MR-proADM levels were associated with higher risk of 30-day mortality and 30-day poor outcomes in a cohort of critically ill patients with COVID-19.
PB MDPI
SN 1999-4915
YR 2021
FD 2021-12-06
LK https://hdl.handle.net/20.500.14352/129437
UL https://hdl.handle.net/20.500.14352/129437
LA eng
NO Oblitas CM, Galeano-Valle F, Ramírez-Navarro J, López-Cano J, Monterrubio-Manrique A, García-Gámiz M, Sancho-González M, Arenal-López S, Álvarez-Sala Walther L, Demelo-Rodríguez P. Mid-regional pro-adrenomedullin, methemoglobin and car-boxyhemoglobin as prognosis biomarkers in critically ill pa-tients with COVID-19: an observational prospective study. Viruses. 2021;13(12):2445. https://doi.org/10.3390/v13122445
DS Docta Complutense
RD 20 ene 2026